

Status: Point in time view as at 22/02/2005.

Changes to legislation: There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

[^{F1}ANNEX I

LIST OF PHARMACOLOGICALLY ACTIVE SUBSTANCES FOR WHICH MAXIMUM RESIDUE LIMITS HAVE BEEN FIXED

Textual Amendments

F1 Substituted by Commission Regulation (EC) No 508/1999 of 4 March 1999 amending Annexes I to IV to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin.

1. Anti-infectious agents

1.1. Chemotherapeutics

1.1.1. Sulfonamides

Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
All substances belonging to the sulfonamide group	Parent drug	All food-producing species	100 µg/kg	Muscle	The combined total residues of all substances within the sulfonamide group should not exceed 100 µg/kg
			100 µg/kg	Fat	
			100 µg/kg	Liver	
			100 µg/kg	Kidney	
		Bovine, ovine, caprine	Milk		

1.1.2. Diamino pyrimidine derivatives

Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Baquiloprim	Baquiloprim	Bovine	10 µg/kg	Fat	
			300 µg/kg	Liver	
			150 µg/kg	Kidney	

a [^{F2}For porcine and poultry species this MRL relates to 'skin and fat in natural proportions'.

b For fin fish this MRL relates to 'muscle and skin in natural proportions'.]

Status: Point in time view as at 22/02/2005.

Changes to legislation: There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

			30 µg/kg	Milk	
		Porcine	40 µg/kg	Skin and fat	
			50 µg/kg	Liver	
			50 µg/kg	Kidney	
[^{F3} Trimethoprim]	Trimethoprim	All food producing species except equidae	50 µg/kg	Fat ^a	Not for use in animals from which eggs are produced for human consumption
			50 µg/kg	Muscle ^b	
			50 µg/kg	Liver	
			50 µg/kg	Kidney	
			50 µg/kg	Milk	
		Equidae	100 µg/kg	Muscle	
			100 µg/kg	Fat	
			100 µg/kg	Liver	
			100 µg/kg	Kidney]	

a [^{F2}For porcine and poultry species this MRL relates to 'skin and fat in natural proportions'.

b For fin fish this MRL relates to 'muscle and skin in natural proportions'.]

Textual Amendments

F2 Inserted by Commission Regulation (EC) No 1181/2002 of 1 July 2002 amending Annex I of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F3 Substituted by Commission Regulation (EC) No 1181/2002 of 1 July 2002 amending Annex I of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

1.2. Antibiotics

1.2.1. Penicillins

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Amoxicillin	Amoxicillin	All food-producing species	50 µg/kg	Muscle	
			50 µg/kg	Fat	
			50 µg/kg	Liver	
			50 µg/kg	Kidney	
			4 µg/kg	Milk	

a [^{F4}For intramammary use only.]

*Status: Point in time view as at 22/02/2005.***Changes to legislation:** There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

Ampicillin	Ampicillin	All food-producing species	50 µg/kg	Muscle	
			50 µg/kg	Fat	
			50 µg/kg	Liver	
			50 µg/kg	Kidney	
			4 µg/kg	Milk	
Benzylpenicillin	Benzylpenicillin	All food-producing species	50 µg/kg	Muscle	
			50 µg/kg	Fat	
			50 µg/kg	Liver	
			50 µg/kg	Kidney	
			4 µg/kg	Milk	
Cloxacillin	Cloxacillin	All food-producing species	300 µg/kg	Muscle	
			300 µg/kg	Fat	
			300 µg/kg	Liver	
			300 µg/kg	Kidney	
			30 µg/kg	Milk	
Dicloxacillin	Dicloxacillin	All food-producing species	300 µg/kg	Muscle	
			300 µg/kg	Fat	
			300 µg/kg	Liver	
			300 µg/kg	Kidney	
			30 µg/kg	Milk	
[^{F5} Nafcillin	Nafcillin	All ruminants ^a	300 µg/kg	Muscle	
			300 µg/kg	Fat	
			300 µg/kg	Liver	
			300 µg/kg	Kidney	
			30 µg/kg	Milk]	
Oxacillin	Oxacillin	All food-producing species	300 µg/kg	Muscle	
			300 µg/kg	Fat	

^a [^{F4}For intramammary use only.]

Status: Point in time view as at 22/02/2005.

Changes to legislation: There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

			300 µg/kg	Liver	
			300 µg/kg	Kidney	
			30 µg/kg	Milk	
Penethamate	Benzylpenicillin	Bovine	50 µg/kg	Muscle	
			50 µg/kg	Fat	
			50 µg/kg	Liver	
			50 µg/kg	Kidney	
			4 µg/kg	Milk	
[^{F6}		Porcine	50 µg/kg	Muscle	
			50 µg/kg	Fat	
			50 µg/kg	Liver	
			50 µg/kg	Kidney]
[^{F7}	Phenoxyethylpenicillin	Porcine	25 µg/kg	Muscle	
			25 µg/kg	Liver	
			25 µg/kg	Kidney]

a [^{F4}For intramammary use only.]

Textual Amendments

- F4** Inserted by Commission Regulation (EC) No 546/2004 of 24 March 2004 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- F5** Substituted by Commission Regulation (EC) No 546/2004 of 24 March 2004 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- F6** Inserted by Commission Regulation (EC) No 2757/1999 of 22 December 1999 amending Annexes I and II of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- F7** Inserted by Commission Regulation (EC) No 1286/2000 of 19 June 2000 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

1.2.2. Cephalosporins

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions

*Status: Point in time view as at 22/02/2005.***Changes to legislation:** There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

[^{F8} Cefacetrile	Cefacetrile	Bovine	125 µg/kg	Milk	For intramammary use only]
[^{F9} Cefalexin	Cefalexin	Bovine	200 µg/kg	Muscle	
			200 µg/kg	Fat	
			200 µg/kg	Liver	
			1 000 µg/kg	Kidney	
			100 µg/kg	Milk]
[^{F10} Cefalonium	Cefalonium	Bovine	20 µg/kg	Milk]
[^{F11} Cefapirin	Sum of cephalapirin and desacetylcephapirin	Bovine	50 µg/kg	Muscle	
			50 µg/kg	Fat	
			100 µg/kg	Kidney	
			60 µg/kg	Milk]
Cefazolin	Cefazolin	Bovine, ovine, caprine	50 µg/kg	Milk	
[^{F12} Cefoperazon	Cefoperazone	Bovine	50 µg/kg	Milk]
Cefquinome	Cefquinome	Bovine	50 µg/kg	Muscle	
			50 µg/kg	Fat	
			100 µg/kg	Liver	
			200 µg/kg	Kidney	
			20 µg/kg	Milk	
[^{F13}		Porcine	50 µg/kg	Muscle	
			50 µg/kg	Skin + fat	
			100 µg/kg	Liver	
			200 µg/kg	Kidney]
[^{F14}		Equidae	50 µg/kg	Muscle	
			50 µg/kg	Fat	
			100 µg/kg	Liver	
			200 µg/kg	Kidney]
[^{F15} Ceftiofur	Sum of all residues retaining the betalactam structure expressed as desfuroylceftiofur	Bovine	1 000 µg/kg	Muscle	
			2 000 µg/kg	Fat	
			2 000 µg/kg	Liver	
			6 000 µg/kg	Kidney	
			100 µg/kg	[^{F16} Milk]	
		Porcine	1 000 µg/kg	Muscle	

Status: Point in time view as at 22/02/2005.

Changes to legislation: There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

		2 000 µg/kg	Fat	
		2 000 µg/kg	Liver	
		6 000 µg/kg	Kidney	I

Textual Amendments

- F8** Inserted by Commission Regulation (EC) No 2162/2001 of 7 November 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- F9** Inserted by Commission Regulation (EC) No 2728/1999 of 20 December 1999 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- F10** Inserted by Commission Regulation (EC) No 61/2003 of 15 January 2003 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- F11** Inserted by Commission Regulation (EC) No 1553/2001 of 30 July 2001 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- F12** Inserted by Commission Regulation (EC) No 807/2001 of 25 April 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- F13** Inserted by Commission Regulation (EC) No 1931/1999 of 9 September 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- F14** Inserted by Commission Regulation (EC) No 2145/2003 of 8 December 2003 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- F15** Inserted by Commission Regulation (EC) No 804/1999 of 16 April 1999 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- F16** Substituted by Commission Regulation (EC) No 1752/2002 of 1 October 2002 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

1.2.3. Quinolones

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
a	[² For fin fish this MRL relates to 'muscle and skin in natural proportions'.				
b	For porcine species this MRL relates to 'skin and fat in natural proportions'.]				

*Status: Point in time view as at 22/02/2005.***Changes to legislation:** There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

[^{F3} Danofloxacin]	Danofloxacin	[^{X1} All food producing species except bovine, ovine, caprine, porcine and poultry]	100 µg/kg	Muscle ^b			
			50 µg/kg	Fat ^a			
			200 µg/kg	Liver			
			200 µg/kg	Kidney			
		Bovine, ovine, caprine	200 µg/kg	Muscle			
			100 µg/kg	Fat			
			400 µg/kg	Liver			
			400 µg/kg	Kidney			
			30 µg/kg	Milk			
		Poultry	200 µg/kg	Muscle	Not for use in animals from which eggs are produced for human consumption		
			100 µg/kg	Skin and fat			
			400 µg/kg	Liver			
			400 µg/kg	Kidney			
		Difloxacin	Difloxacin	All food producing species except bovine, ovine, caprine and poultry	300 µg/kg	Muscle ^b	
					100 µg/kg	Fat	
					800 µg/kg	Liver	
600 µg/kg	Kidney						
Bovine, ovine, caprine	400 µg/kg			Muscle	Not for use in animals from which milk is produced for human consumption		
	100 µg/kg			Fat			
	1 400 µg/kg			Liver			
	800 µg/kg			Kidney			
Porcine	400 µg/kg			Muscle			
	100 µg/kg			Skin and fat			
	800 µg/kg			Liver			
	800 µg/kg			Kidney			
Poultry	300 µg/kg			Muscle	Not for use in animals from which eggs are produced for human consumption		
	400 µg/kg			Skin and fat			
	1 900 µg/kg			Liver			
	600 µg/kg			Kidney			

a [^{F2}For fin fish this MRL relates to 'muscle and skin in natural proportions'.**b** For porcine species this MRL relates to 'skin and fat in natural proportions'.]

Status: Point in time view as at 22/02/2005.

Changes to legislation: There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

Enrofloxacin	Sum of enrofloxacin and ciprofloxacin	All food producing species except bovine, ovine, caprine, porcine, rabbits and poultry	100 µg/kg	Muscle ^b			
			100 µg/kg	Fat			
			200 µg/kg	Liver			
			200 µg/kg	Kidney			
		Bovine, ovine, caprine	100 µg/kg	Muscle			
			100 µg/kg	Fat			
			300 µg/kg	Liver			
			200 µg/kg	Kidney			
			100 µg/kg	Milk			
		Porcine, rabbits	100 µg/kg	Muscle			
			100 µg/kg	Fat ^a			
			200 µg/kg	Liver			
			300 µg/kg	Kidney			
		Poultry	100 µg/kg	Muscle	Not for use in animals from which eggs are produced for human consumption		
			100 µg/kg	Skin and fat			
			200 µg/kg	Liver			
			300 µg/kg	Kidney			
		Flumequine	Flumequine	All food producing species except bovine, ovine, caprine, porcine, poultry and fin fish	200 µg/kg	Muscle	
					250 µg/kg	Fat	
					500 µg/kg	Liver	
1 000 µg/kg	Kidney						
Bovine, porcine, ovine, caprine	200 µg/kg			Muscle			
	300 µg/kg			Fat ^a			
	500 µg/kg			Liver			
	1 500 µg/kg			Kidney			
	50 µg/kg			Milk			
Poultry	400 µg/kg			Muscle	Not for use in animals from		
	250 µg/kg			Skin and fat			

a [²For fin fish this MRL relates to 'muscle and skin in natural proportions'.

b For porcine species this MRL relates to 'skin and fat in natural proportions'.]

*Status: Point in time view as at 22/02/2005.***Changes to legislation:** There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

			800 µg/kg	Liver	which eggs are produced for human consumption		
			1 000 µg/kg	Kidney			
		Fin fish	600 µg/kg	Muscle and skin in natural proportion]]		
[^{F17} Marbofloxacin	Marbofloxacin	Bovine	150 µg/kg	Muscle			
			50 µg/kg	Fat			
			150 µg/kg	Liver			
			150 µg/kg	Kidney			
			75 µg/kg	Milk			
		Porcine	150 µg/kg	Muscle			
			50 µg/kg	Skin and fat			
			150 µg/kg	Liver			
			150 µg/kg	Kidney]]		
[^{F18} Oxolinic acid	Oxolinic acid	Porcine	100 µg/kg	Muscle			
			50 µg/kg	Skin and fat			
			150 µg/kg	Liver			
			150 µg/kg	Kidney			
		Chicken	100 µg/kg	Muscle	Not for use in animals from which eggs are produced for human consumption		
			50 µg/kg	Skin and fat			
			150 µg/kg	Liver			
			150 µg/kg	Kidney			
				Fin fish	100 µg/kg	Muscle and skin in natural proportions]]
		Sarafloxacin	Sarafloxacin	Chicken	10 µg/kg	Skin and fat	
100 µg/kg	Liver						
		Salmonidae	30 µg/kg	Muscle and skin in natural proportions			

a [^{F2}For fin fish this MRL relates to ‘muscle and skin in natural proportions’.

b For porcine species this MRL relates to ‘skin and fat in natural proportions’.]

Status: Point in time view as at 22/02/2005.

Changes to legislation: There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

Editorial Information

- X1** Substituted by [Corrigendum to Commission Regulation \(EC\) No 1181/2002 of 1 July 2002 amending Annex I of Council Regulation \(EEC\) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin \(Official Journal of the European Communities L 172 of 2 July 2002\)](#).

Textual Amendments

- F17** Inserted by [Commission Regulation \(EC\) No 2338/2000 of 20 October 2000 amending Annexes I, II and III to Council Regulation \(EEC\) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin \(Text with EEA relevance\)](#).
- F18** Inserted by [Commission Regulation \(EC\) No 739/2003 of 28 April 2003 amending Annex I to Council Regulation \(EEC\) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin \(Text with EEA relevance\)](#).

1.2.4. Macrolides

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
[^{F20} Acetylisovaleryltirosin]	Sum of acetyl-isovaleryltirosin and 3-O-acetyltyrosin	Porcine	50 µg/kg	Muscle	
			50 µg/kg	Skin and fat	
			50 µg/kg	Liver	
			50 µg/kg	Kidney	l
[^{F3} Erythromycin A]	Erythromycin A	All food producing species	200 µg/kg	Muscle ^a	
			200 µg/kg	Fat ^b	
			200 µg/kg	Liver	
			200 µg/kg	Kidney	
			40 µg/kg	Milk	
			150 µg/kg	Eggs	l
Spiramycin	Sum of spiramycin and neospiramycin	Bovine	200 µg/kg	Muscle	
			300 µg/kg	Fat	
			300 µg/kg	Liver	
			300 µg/kg	Kidney	

a [^{F2}For fin fish this MRL relates to a 'muscle and skin in natural proportions'.

b For porcine species this MRL relates to 'skin and fat in natural proportions'.

c For porcine and poultry species this MRL relates to 'skin and fat in natural proportions'.

d [^{F19}[^{X2}Not for use in animals from which milk is produced for human consumption.]]

Status: Point in time view as at 22/02/2005.

Changes to legislation: There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

			200 µg/kg	Milk	
		Chicken	200 µg/kg	Muscle	
			300 µg/kg	Skin and fat	
			400 µg/kg	Liver	
[^{F21}	Spiramycin 1	Porcine	250 µg/kg	Muscle	
			2 000 µg/kg	Liver	
			1 000 µg/kg	Kidney	I
[^{F3}	Tilmicosin	All food producing species except poultry	50 µg/kg	Muscle ^a	
			50 µg/kg	Fat ^b	
			1 000 µg/kg	Liver	
			1 000 µg/kg	Kidney	
			50 µg/kg	Milk	
		Poultry	75 µg/kg	Muscle	Not for use in animals from which eggs are produced for human consumption
			75 µg/kg	Skin and fat	
			1 000 µg/kg	Liver	
250 µg/kg	Kidney				
[^{F19}][^{X2}	Tulathromycin (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10,13-tetrahydroxy-3,5,8,10,12,14-hexamethyl-11-[[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylohexopyranosyl]oxy]-1-oxa-6-azacyclopent-decan-15-one expressed as tulathromycin equivalents	Bovine	100 µg/kg	Fat	
			3 000 µg/kg	Liver	
			3 000 µg/kg	Kidney	
		Porcine	100 µg/kg	Skin + fat	
			3 000 µg/kg	Liver	
			3 000 µg/kg	Kidney	II
Tylosin	Tylosin A	All food producing species	100 µg/kg	Fat ^c	
			100 µg/kg	Muscle ^a	
			100 µg/kg	Liver	

a [^{F2}For fin fish this MRL relates to a 'muscle and skin in natural proportions'.

b For porcine species this MRL relates to 'skin and fat in natural proportions'.

c For porcine and poultry species this MRL relates to 'skin and fat in natural proportions'.

d [^{F19}][^{X2}Not for use in animals from which milk is produced for human consumption.]]

Status: Point in time view as at 22/02/2005.

Changes to legislation: There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

			100 µg/kg	Kidney	
			50 µg/kg	Milk	
			200 µg/kg	Eggs	l
a	[^{F2} For fin fish this MRL relates to a 'muscle and skin in natural proportions'.				
b	For porcine species this MRL relates to 'skin and fat in natural proportions'.				
c	For porcine and poultry species this MRL relates to 'skin and fat in natural proportions'.				
d	[^{F19} [^{X2} Not for use in animals from which milk is produced for human consumption.]]]				

Editorial Information

- X2** Substituted by Corrigendum to Commission Regulation (EC) No 1101/2004 of 10 June 2004 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Official Journal of the European Union L 211 of 12 June 2004).

Textual Amendments

- F19** Inserted by Commission Regulation (EC) No 1101/2004 of 10 June 2004 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- F20** Inserted by Commission Regulation (EC) No 77/2002 of 17 January 2002 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- F21** Inserted by Commission Regulation (EC) No 2593/1999 of 8 December 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

1.2.5. Florfenicol and related compounds

Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
[^{F3} Florfenicol	Sum of florfenicol and its metabolites measured as florfenicol-amine	All food producing species except bovine, ovine, caprine, porcine, poultry and fin fish	100 µg/kg	Muscle	
			200 µg/kg	Fat	
			2 000 µg/kg	Liver	
			300 µg/kg	Kidney	
		Bovine, ovine, caprine	200 µg/kg	Muscle	Not for use in animals from which milk is produced
			[^{X3} 3 000 µg/kg]	[^{X3} Liver]	
			300 µg/kg	Kidney	

*Status: Point in time view as at 22/02/2005.***Changes to legislation:** There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

					for human consumption
		Porcine	300 µg/kg	Muscle	
			500 µg/kg	Skin and fat	
			2 000 µg/kg	Liver	
			500 µg/kg	Kidney	
		Poultry	100 µg/kg	Muscle	Not for use in animals from which eggs are produced for human consumption
			200 µg/kg	Skin and fat	
			2 500 µg/kg	Liver	
			750 µg/kg	Kidney	
		Fin fish	1 000 µg/kg	Muscle and skin in natural proportions]]
Thiamphenicol	Thiamphenicol	Bovine	50 µg/kg	Muscle	
			50 µg/kg	Fat	
			50 µg/kg	Liver	
			50 µg/kg	Kidney	
			50 µg/kg	Milk	
			Chicken	50 µg/kg	Muscle
		Not for use in animals from which eggs are produced for human consumption	50 µg/kg	Skin and fat	
			50 µg/kg	Liver	
			50 µg/kg	Kidney	

Editorial Information

X3 Substituted by Corrigendum to Commission Regulation (EC) No 1181/2002 of 1 July 2002 amending Annex I of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Official Journal of the European Communities L 172 of 2 July 2002).

1.2.6. Tetracyclines

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
-------------------------------------	----------------	----------------	------	----------------	------------------

Status: Point in time view as at 22/02/2005.

Changes to legislation: There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

Chlortetracycline	Sum of parent drug and its 4-epimer	All food-producing species	100 µg/kg	Muscle	
			300 µg/kg	Liver	
			600 µg/kg	Kidney	
			100 µg/kg	Milk	
			200 µg/kg	Eggs	
Doxycycline	Doxycycline	Bovine	100 µg/kg	Muscle	
		Not for use in animals from which milk is produced for human consumption	300 µg/kg	Liver	
			600 µg/kg	Kidney	
		Porcine	100 µg/kg	Muscle	
			300 µg/kg	Skin and fat	
			300 µg/kg	Liver	
			600 µg/kg	Kidney	
		Poultry	100 µg/kg	Muscle	
		Not for use in animals from which eggs are produced for human consumption	300 µg/kg	Skin and fat	
			300 µg/kg	Liver	
			600 µg/kg	Kidney	
Oxytetracycline	Sum of parent drug and its 4-epimer	All food-producing species	100 µg/kg	Muscle	
			300 µg/kg	Liver	
			600 µg/kg	Kidney	
			100 µg/kg	Milk	
			200 µg/kg	Eggs	
Tetracycline	Sum of parent drug and its 4-epimer	All food-producing species	100 µg/kg	Muscle	
			300 µg/kg	Liver	
			600 µg/kg	Kidney	

*Status: Point in time view as at 22/02/2005.**Changes to legislation: There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)*

			100 µg/kg	Milk	
			200 µg/kg	Eggs	

1.2.7. Naphtalene-ringed ansamycin

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Rifaximin	Rifaximin	Bovine	60 µg/kg	Milk	

1.2.8. Pleuromutilines

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
[^{F9} Tiamulin	Sum of metabolites that may be hydrolysed to 8-a-hydroxymutilin	Porcine	100 µg/kg	Muscle	
			500 µg/kg	Liver	
		Chicken	100 µg/kg	Muscle	
			100 µg/kg	Skin and fat	
			1 000 µg/kg	Liver	
		[^{F17} Rabbits	100 µg/kg	Muscle	
			500 µg/kg	Liver]
		[^{F12} Turkey	100 µg/kg	Muscle	
			100 µg/kg	Skin and fat	
			300 µg/kg	Liver]
	Tiamulin		1 000 µg/kg	Eggs]
Valnemulin	Valnemulin	Porcine	50 µg/kg	Muscle	
			500 µg/kg	Liver	
			100 µg/kg	Kidney	

[^{F15}1.2.9. Lincosamides

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
[^{F3} Lincomycin	Lincomycin	All food producing species	50 µg/kg	Fat ^a	
			100 µg/kg	Muscle ^b	

^a [^{F2}For porcine and poultry species this MRL relates to 'skin and fat in natural proportions'.^b For fin fish this MRL relates to 'muscle and skin in natural proportions'.]

Status: Point in time view as at 22/02/2005.

Changes to legislation: There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

			500 µg/kg	Liver	
			1 500 µg/kg	Kidney	
			150 µg/kg	Milk	
			50 µg/kg	Eggs]]
[^{F17} Pirlimycin	Pirlimycin	Bovine	100 µg/kg	Muscle	
			100 µg/kg	Fat	
			1 000 µg/kg	Liver	
			400 µg/kg	Kidney	
			100 µg/kg	Milk	
		Porcine	100 µg/kg	Muscle	
			50 µg/kg	Skin and fat	
			500 µg/kg	Liver	
			1 500 µg/kg	Kidney	
		Chicken	100 µg/kg	Muscle	
			50 µg/kg	Skin and fat	
			500 µg/kg	Liver	
			1 500 µg/kg	Kidney	
			50 µg/kg	Eggs]]

a [^{F2}For porcine and poultry species this MRL relates to 'skin and fat in natural proportions'.

b For fin fish this MRL relates to 'muscle and skin in natural proportions'.]]

[^{F13}1.2.10 Aminoglycosides

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Apramycin	Apramycin	Bovine	1 000 µg/kg	Muscle	Not for use in animals from which milk is produced for human consumption
			1 000 µg/kg	Fat	
			10 000 µg/kg	Liver	
			20 000 µg/kg	Kidney	
[^{F23} Dihydrostreptomycin	Dihydrostreptomycin	Bovine, ovine	500 µg/kg	Muscle	
			500 µg/kg	Fat	
			500 µg/kg	Liver	

a [^{F2}For porcine and poultry species this MRL relates to 'skin and fat in natural proportions'.

b For fin fish this MRL relates to 'muscle and skin in natural proportions'.

c [^{F22}Not for use in animals from which eggs are produced for human consumption.]]]

Status: Point in time view as at 22/02/2005.

Changes to legislation: There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

			1 000 µg/kg	Kidney	
			200 µg/kg	Milk	
		Porcine	500 µg/kg	Muscle	
			500 µg/kg	Skin and fat	
			500 µg/kg	Liver	
			1 000 µg/kg	Kidney]
[^{F24} Gentamicin	Sum of gentamicin C1, gentamicin C1a, gentamicin C2 and gentamicin C2a	Bovine	50 µg/kg	Muscle	
			50 µg/kg	Fat	
			200 µg/kg	Liver	
			750 µg/kg	Kidney	
			100 µg/kg	Milk	
		Porcine	50 µg/kg	Muscle	
			50 µg/kg	Skin and fat	
			200 µg/kg	Liver	
			750 µg/kg	Kidney]
[^{F22} Kanamycin	Kanamycin A	All food producing species except fish ^c	100 µg/kg	Muscle	
			100 µg/kg	Fat ^a	
			600 µg/kg	Liver	
			2 500 µg/kg	Kidney	
			150 µg/kg	Milk]
[^{F2} Neomycin (including framycetin)	Neomycin B	All food producing species	500 µg/kg	Fat ^a	
			500 µg/kg	Muscle ^b	
			500 µg/kg	Liver	
			5 000 µg/kg	Kidney	
			1 500 µg/kg	Milk	
			500 µg/kg	Eggs]
[^{F3} Paromomycin	Paromomycin	All food producing species	500 µg/kg	Muscle ^b	Not for use in animals from which milk or eggs are produced for human consumption
			1 500 µg/kg	Liver	
			1 500 µg/kg	Kidney	

a [^{F2}For porcine and poultry species this MRL relates to 'skin and fat in natural proportions'.

b For fin fish this MRL relates to 'muscle and skin in natural proportions'.

c [^{F22}Not for use in animals from which eggs are produced for human consumption.]]]

Status: Point in time view as at 22/02/2005.

Changes to legislation: There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

Spectinomycin	Spectinomycin	All food producing species except ovine	500 µg/kg	Fat ^a	Not for use in animals from which eggs are produced for human consumption
			300 µg/kg	Muscle ^b	
			1 000 µg/kg	Liver	
			5 000 µg/kg	Kidney	
			200 µg/kg	Milk	
		Ovine	300 µg/kg	Muscle	
			500 µg/kg	Fat	
			2 000 µg/kg	Liver	
			5 000 µg/kg	Kidney	
			200 µg/kg	Milk]	
[^{F23} Streptomycin	Streptomycin	Bovine, ovine	500 µg/kg	Muscle	
			500 µg/kg	Fat	
			500 µg/kg	Liver	
			1 000 µg/kg	Kidney	
			200 µg/kg	Milk	
		Porcine	500 µg/kg	Muscle	
			500 µg/kg	Skin and fat	
			500 µg/kg	Liver	
			1 000 µg/kg	Kidney	

a [^{F2}For porcine and poultry species this MRL relates to 'skin and fat in natural proportions'.

b For fin fish this MRL relates to 'muscle and skin in natural proportions'.

c [^{F22}Not for use in animals from which eggs are produced for human consumption.]]

Textual Amendments

F22 Inserted by Commission Regulation (EC) No 324/2004 of 25 February 2004 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F23 Inserted by Commission Regulation (EC) No 1530/2002 of 27 August 2002 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F24 Inserted by Commission Regulation (EC) No 868/2002 of 24 May 2002 amending Annexes I and II of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

[^{F21}1.2.11.Other antibiotics

Status: Point in time view as at 22/02/2005.

Changes to legislation: There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Novobiocin	Novobiocin	Bovine	50 µg/kg	Milk	I

[^{F25}1.2.12] Polypeptides

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Bacitracin	Sum of bacitracin A, bacitracin B, and bacitracin C	Bovine	100 µg/kg	Milk	
[^{F26}		Rabbits	150 µg/kg	Muscle	
			150 µg/kg	Fat	
			150 µg/kg	Liver	
			150 µg/kg	Kidney	II

Textual Amendments

F26 Inserted by Commission Regulation (EC) No 544/2003 of 27 March 2003 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

Textual Amendments

F25 Inserted by Commission Regulation (EC) No 1478/2001 of 18 July 2001 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

[^{F11}1.2.13] Beta-lactamase inhibitors

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Clavulanic acid	Clavulanic acid	Bovine	100 µg/kg	Muscle	
			100 µg/kg	Fat	
			200 µg/kg	Liver	
			400 µg/kg	Kidney	
			200 µg/kg	Milk	

Status: Point in time view as at 22/02/2005.

Changes to legislation: There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

		Porcine	100 µg/kg	Muscle	
			100 µg/kg	Skin and fat	
			200 µg/kg	Liver	
			400 µg/kg	Kidney]

[^{F21}1.2.14. Polymyxins

Pharmacological active substance	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Colistin	Colistin	All food producing species	150 µg/kg	Fat ^a	
			150 µg/kg	Muscle ^b	
			150 µg/kg	Liver	
			200 µg/kg	Kidney	
			50 µg/kg	Milk	
			300 µg/kg	Eggs	

a For porcine and poultry species this MRL relates to 'skin and fat in natural proportions'.

b For fin fish this MRL relates to 'muscle and skin in natural proportions'.

2. Antiparasitic agents

2.1. Agents acting against endoparasites

2.1.1. Salicylanilides

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Closantel	Closantel	Bovine	1 000 µg/kg	Muscle	
			3 000 µg/kg	Fat	
			1 000 µg/kg	Liver	
			3 000 µg/kg	Kidney	
		Ovine	1 500 µg/kg	Muscle	
			2 000 µg/kg	Fat	
			1 500 µg/kg	Liver	
			5 000 µg/kg	Kidney	
[^{F25} Rafoxanide	Rafoxanide	Bovine	30 µg/kg	Muscle	Not for use in animals from which milk is produced
			30 µg/kg	Fat	
			10 µg/kg	Liver	

*Status: Point in time view as at 22/02/2005.**Changes to legislation: There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)*

			40 µg/kg	Kidney	for human consumption
	Ovine		100 µg/kg	Muscle	
			250 µg/kg	Fat	
			150 µg/kg	Liver	
			150 µg/kg	Kidney]	

2.1.2. Tatra-hydro-imidazoles (imidazolthiazoles)

Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Levamisole	Levamisole	Bovine, ovine, porcine, poultry	10 µg/kg	Muscle	
			10 µg/kg	Fat	
			100 µg/kg	Liver	
			10 µg/kg	Kidney	

2.1.3. Benzimidazoles and pro-benzimidazoles

Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
[^{F27} Albendazole	Sum of albendazole sulphoxide, albendazole sulphone, and albendazole 2-amino sulphone, expressed as albendazole	All ruminants	100 µg/kg	Muscle	
			100 µg/kg	Fat	
			1 000 µg/kg	Liver	
			500 µg/kg	Kidney	
			100 µg/kg	Milk]	
[^{F28} Albendazole oxide	Sum of albendazole oxide, albendazole sulphone and albendazole 2-aminosulphone, expressed as albendazole	Bovine, ovine	100 µg/kg	Muscle	
			100 µg/kg	Fat	
			1 000 µg/kg	Liver	
			500 µg/kg	Kidney	
			100 µg/kg	Milk	

Status: Point in time view as at 22/02/2005.

Changes to legislation: There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

[^{F27} Febantel	Sum of extractable residues which may be oxidised to oxfendazole sulphone	All ruminants	50 µg/kg	Muscle	
			50 µg/kg	Fat	
			500 µg/kg	Liver	
			50 µg/kg	Kidney	
			10 µg/kg	Milk	
Fenbendazole	Sum of extractable residues which may be oxidised to oxfendazole sulphone	All ruminants	50 µg/kg	Muscle	
			50 µg/kg	Fat	
			500 µg/kg	Liver	
			50 µg/kg	Kidney	
			10 µg/kg	Milk]	
Flubendazole	Sum of flubendazole and (2-amino 1H-benzimidazol-5-yl) (4fluorophenyl) methanone	Porcine, chicken, game birds	50 µg/kg	Muscle	
			50 µg/kg	Skin and fat	
			400 µg/kg	Liver	
			300 µg/kg	Kidney	
			50 µg/kg	Muscle	
[^{F29}		Turkey	50 µg/kg	Muscle	
			50 µg/kg	Skin and fat	
			400 µg/kg	Liver	
			300 µg/kg	Kidney	
			400 µg/kg	Eggs	
[^{F30} Mebendazole	Sum of mebendazole methyl (5-(1-hydroxy, 1-phenyl) methyl-1H-benzimidazol-2-yl) carbamate and (2-amino-1H-benzimidazol-5-yl) phenylmethanone, expressed as mebendazole equivalents	Ovine, caprine, equidae	60 µg/kg	Muscle	Not for use in animals from which milk is produced for human consumption
			60 µg/kg	Fat	
			400 µg/kg	Liver	
			60 µg/kg	Kidney]	

*Status: Point in time view as at 22/02/2005.**Changes to legislation: There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)*

[^{F12} Netobimin]	Sum of albendazole oxide, albendazole sulphone and albendazole 2-aminosulphone, expressed as albendazole	[^{X4} Bovine, ovine]	100 µg/kg	Muscle	For oral use only
			100 µg/kg	Fat	
			1 000 µg/kg	Liver	
			500 µg/kg	Kidney	
			100 µg/kg	Milk]	
[^{F27} Oxfendazole]	Sum of extractable residues which may be oxidised to oxfendazole sulphone	All ruminants	50 µg/kg	Muscle	
			50 µg/kg	Fat	
			500 µg/kg	Liver	
			50 µg/kg	Kidney	
			10 µg/kg	Milk]	
Oxibendazole	Oxibendazole	Porcine	100 µg/kg	Muscle	
			500 µg/kg	Skin and fat	
			200 µg/kg	Liver	
			100 µg/kg	Kidney	
[^{F27} Thiabendazole]	Sum of thiabendazole and 5-hydroxythiabendazole	Caprine	100 µg/kg	Muscle	
			100 µg/kg	Fat	
			100 µg/kg	Liver	
			100 µg/kg	Kidney	
			100 µg/kg	Milk]	
Triclabendazole	Sum of extractable residues that may be oxidised to ketotriclabendazole	Bovine, ovine	100 µg/kg	Muscle	Not for use in animals from which milk is produced for human consumption
			100 µg/kg	Liver	
			100 µg/kg	Kidney	

Editorial Information

- X4** Substituted by [Corrigendum to Commission Regulation \(EC\) No 807/2001 of 25 April 2001 amending Annexes I, II and III to Council Regulation \(EEC\) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin \(Official Journal of the European Communities L 118 of 27 April 2001\)](#).

Status: Point in time view as at 22/02/2005.

Changes to legislation: There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

Textual Amendments

- F27** Substituted by Commission Regulation (EC) No 1646/2004 of 20 September 2004 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- F28** Inserted by Commission Regulation (EC) No 2393/1999 of 11 November 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- F29** Inserted by Commission Regulation (EC) No 2385/1999 of 10 November 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- F30** Inserted by Commission Regulation (EC) No 1680/2001 of 22 August 2001 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

[^{F31}2.1.4. Phenol derivatives including salicylanides

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Nitroxinil	Nitroxinil	Bovine, ovine	400 µg/kg	Muscle	
			200 µg/kg	Fat	
			20 µg/kg	Liver	
			400 µg/kg	Kidney	
[^{F27} Oxyclozanide	Oxyclozanide	All ruminants	20 µg/kg	Muscle	
			20 µg/kg	Fat	
			500 µg/kg	Liver	
			100 µg/kg	Kidney	
			10 µg/kg	Milk]]	

Textual Amendments

- F31** Inserted by Commission Regulation (EC) No 997/1999 of 11 May 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

[^{F32}2.1.5. Benzenesulphonamides

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
-------------------------------------	----------------	----------------	------	----------------	------------------

Status: Point in time view as at 22/02/2005.

Changes to legislation: There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

Clorsulon	Clorsulon	Bovine	35 µg/kg	Muscle	
			100 µg/kg	Liver	
			200 µg/kg	Kidney]

Textual Amendments

F32 Inserted by Commission Regulation (EC) No 1942/1999 of 10 September 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

[^{F24}2.1.6. Piperazine derivatives

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Piperazine	Piperazine	Porcine	400 µg/kg	Muscle	
			800 µg/kg	Skind and fat	
			2 000 µg/kg	Liver	
			1 000 µg/kg	Kidney	
		Chicken	2 000 µg/kg	Eggs]

[^{F33}2.1.7. Tetrahydropyrimides

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Morantel	Sum of residues which may be hydrolysed to N-methyl-1,3-propanediamine and expressed as morantel equivalents	Bovine, ovine	100 µg/kg	Muscle	
			100 µg/kg	Fat	
			800 µg/kg	Liver	
			200 µg/kg	Kidney	
			50 µg/kg	Milk]

Textual Amendments

F33 Inserted by Commission Regulation (EC) No 1851/2004 of 25 October 2004 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits for veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

Status: Point in time view as at 22/02/2005.

Changes to legislation: There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

2.2. Agents acting against ectoparasites

2.2.1. Organophosphates

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
[^{F25} Coumafos	Coumafos	Bees	100 µg/kg	Honey]
Diazinon	Diazinon	Bovine, ovine, caprine	20 µg/kg	Milk	
		Bovine, porcine, ovine, caprine	20 µg/kg	Muscle	
			700 µg/kg	Fat	
			20 µg/kg	Liver	
			20 µg/kg	Kidney	
[^{F12} Phoxim	Phoxim	Ovine	50 µg/kg	Muscle	Not for use in animals from which milk is produced for human consumption
			400 µg/kg	Fat	
			50 µg/kg	Kidney	
		Porcine	20 µg/kg	Muscle	
			700 µg/kg	Skin and fat	
			20 µg/kg	Liver	
			20 µg/kg	Kidney]	

2.2.2. Formamidines

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Amitraz	Sum of amitraz and all metabolites containing the 2,4-DMA moiety, expressed as amitraz	Bovine	200 µg/kg	Fat	
			200 µg/kg	Liver	
			200 µg/kg	Kidney	
			10 µg/kg	Milk	
		Ovine	400 µg/kg	Fat	

Status: Point in time view as at 22/02/2005.

Changes to legislation: There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

			100 µg/kg	Liver	
			200 µg/kg	Kidney	
			10 µg/kg	Milk	
		Porcine	400 µg/kg	Skin and fat	
			200 µg/kg	Liver	
			200 µg/kg	Kidney	
[^{F28}		Bees (honey)	200 µg/kg	Honey]
[^{F34}		Caprine	200 µg/kg	Fat	
			100 µg/kg	Liver	
			200 µg/kg	Kidney	
			10 µg/kg	Milk]

Textual Amendments

F34 Inserted by [Commission Regulation \(EC\) No 1646/2004 of 20 September 2004 amending Annex I to Council Regulation \(EEC\) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin \(Text with EEA relevance\)](#).

2.2.3. Pyrethroids

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
[^{F12} [^{X4} Cyhalothrin	Cyhalothrin (sum of isomers)	Bovine	500 µg/kg	Fat	Further provisions in Council Directive 94/29/EC are to be observed
			50 µg/kg	Kidney	
			50 µg/kg	Milk	
Cyfluthrin	Cyfluthrin (sum of isomers)	Bovine	10 µg/kg	Muscle	
			50 µg/kg	Fat	
			10 µg/kg	Liver	
			10 µg/kg	Kidney	
			20 µg/kg	Milk]]	
[^{F35} [^{F27} Deltamethrin	Deltamethrin	All ruminants	10 µg/kg	Muscle	
			50 µg/kg	Fat	
			10 µg/kg	Liver	
			10 µg/kg	Kidney	
			20 µg/kg	Milk]	

a [^{F10}Further provisions in Commission Directive 98/82/EC are to be observed (OJ L 290, 29.10.1998, p. 25).]

Status: Point in time view as at 22/02/2005.

Changes to legislation: There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

		[^{F8} Fin fish	10 µg/kg	Muscle and skin in natural proportions]]	
Flumethrin	Flumethrin (sum of trans-Z isomers)	Bovine	10 µg/kg	Muscle	
			150 µg/kg	Fat	
			20 µg/kg	Liver	
			10 µg/kg	Kidney	
			30 µg/kg	Milk	
[^{F36}		Ovine	10 µg/kg	Muscle	Not for use in animals from which milk is produced for human consumption
			150 µg/kg	Fat	
			20 µg/kg	Liver	
			10 µg/kg	Kidney]
[^{F10} Permethrin	Permethrin (sum of isomers)	Bovine	50 µg/kg	Muscle	
			500 µg/kg	Fat	
			50 µg/kg	Liver	
			50 µg/kg	Kidney	
			50 µg/kg	Milk ^a]
[^{F37} Cypermethrin	Cypermethrin (sum of isomers)	Salmonidae	50 µg/kg	Muscle and skin in natural proportions]
		[^{F27} All ruminants	20 µg/kg	Muscle	
			200 µg/kg	Fat	
			20 µg/kg	Liver	
			20 µg/kg	Kidney	
			20 µg/kg	Milk ^a]
[^{F38} Alphacypermethrin	Cypermethrin (sum of isomers)	Bovine, ovine	20 µg/kg	Muscle	
			200 µg/kg	Fat	
			20 µg/kg	Liver	
			20 µg/kg	Kidney	

^a [^{F10}Further provisions in Commission Directive 98/82/EC are to be observed (OJ L 290, 29.10.1998, p. 25).]

Status: Point in time view as at 22/02/2005.

Changes to legislation: There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

		20 µg/kg	Milk] ^a
--	--	----------	--------------------

a [^{F10}Further provisions in Commission Directive 98/82/EC are to be observed (OJ L 290, 29.10.1998, p. 25).]

Textual Amendments

- F35** Inserted by Commission Regulation (EC) No 1815/2001 of 14 September 2001 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- F36** Inserted by Commission Regulation (EC) No 2391/2000 of 27 October 2000 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- F37** Inserted by Commission Regulation (EC) No 1029/2003 of 16 June 2003 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).
- F38** Inserted by Commission Regulation (EC) No 2011/2003 of 14 November 2003 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

[^{F13}2.2.4. Acyl urea derivatives

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
[^{F21} Diflubenzuron]	Diflubenzuron	Salmonidae	1 000 µg/kg	Muscle and skin in natural proportions]
Teflubenzuron	Teflubenzuron	Salmonidae	500 µg/kg	Muscle and skin in natural proportions]

[^{F39}2.2.5. Pyrimidines derivatives

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Dicyclanil	Sum of dicyclanil and 2, 4, 6-triamino-pyrimidine-5-carbonitrile	Ovine	200 µg/kg	Muscle	Not for use in animals from which milk is produced for human consumption
			[^{F40} 150 µg/kg]	Fat	
			400 µg/kg	Liver	
			400 µg/kg	Kidney]	

Status: Point in time view as at 22/02/2005.

Changes to legislation: There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

Textual Amendments

F40 Substituted by Commission Regulation (EC) No 2391/2000 of 27 October 2000 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

Textual Amendments

F39 Inserted by Commission Regulation (EC) No 1960/2000 of 15 September 2000 amending Annexes I and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

[^{F25}2.2.6. Triazine derivatives

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Cyromazine	Cyromazine	Ovine	300 µg/kg	Muscle	Not for use in animals from which milk is produced for human consumption
			300 µg/kg	Fat	
			300 µg/kg	Liver	
			300 µg/kg	Kidney]	

2.3. Agents acting against endo- and ectoparasites

2.3.1. Avermectins

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Abamectin	Avermectin B1a	Bovine	10 µg/kg	Fat	
			20 µg/kg	Liver	
[^{F24}		Ovine	20 µg/kg	Muscle	Not for use in animals from which milk is produced for human consumption
			50 µg/kg	Fat	
			25 µg/kg	Liver	
			20 µg/kg	Kidney	

*Status: Point in time view as at 22/02/2005.***Changes to legislation:** There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

Doramectin	Doramectin	Bovine	10 µg/kg	Muscle	Not for use in bovine from which milk is produced for human consumption
			150 µg/kg	Fat	
			100 µg/kg	Liver	
			30 µg/kg	Kidney	
		Porcine, ovine	20 µg/kg	Muscle	Not for use in ovine from which milk is produced for human consumption
			100 µg/kg	Fat	
			50 µg/kg	Liver	
			30 µg/kg	Kidney	
[^{F25}		Deer, including reindeer	20 µg/kg	Muscle	
			100 µg/kg	Fat	
			50 µg/kg	Liver	
			30 µg/kg	Kidney]
[^{F41} Emamectin	Emamectin B1a	Fin fish	100 µg/kg	Muscle and skin in natural proportions]
Eprinomectin	Eprinomectin B1a	Bovine	[^{F42} 50 µg/kg]	Muscle	
			[^{F42} 250 µg/kg]	Fat	
			[^{F42} 1 500 µg/kg]	Liver	
			[^{F42} 300 µg/kg]	Kidney	
			[^{F42} 20 µg/kg]	Milk	
Ivermectin	22, 23-Dihydro-avermectin B1a	Bovine	40 µg/kg	Fat	
			100 µg/kg	Liver	

Status: Point in time view as at 22/02/2005.

Changes to legislation: There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

		Porcine, ovine, equidae	20 µg/kg	Fat	
			15 µg/kg	Liver	
		Deer, including reindeer	20 µg/kg	Muscle	
			100 µg/kg	Fat	
			50 µg/kg	Liver	
			20 µg/kg	Kidney	
Moxidectin	Moxidectin	Bovine, ovine	50 µg/kg	Muscle	
			500 µg/kg	Fat	
			100 µg/kg	Liver	
			50 µg/kg	Kidney	
[^{F11}		Bovine	40 µg/kg	Milk]
[^{F32}		Equidae	50 µg/kg	Muscle	
			500 µg/kg	Fat	
			100 µg/kg	Liver	
			50 µg/kg	Kidney]

Textual Amendments

F41 Substituted by Commission Regulation (EC) No 1490/2003 of 25 August 2003 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F42 Substituted by Commission Regulation (EC) No 1943/1999 of 10 September 1999 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

2.4. Agents acting against protozoa

2.4.1. Triazinetrione derivative

Pharmacologically active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Toltrazuril	Toltrazuril sulfone	Chicken	100 µg/kg	Muscle	Not for use in animals from which eggs are produced

Status: Point in time view as at 22/02/2005.

Changes to legislation: There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

					for human consumption
			200 µg/kg	Skin and fat	
			600 µg/kg	Liver	
			400 µg/kg	Kidney	
		Turkey	100 µg/kg	Muscle	
			200 µg/kg	Skin and fat	
			600 µg/kg	Liver	
			400 µg/kg	Kidney	
[^{F43}		Porcine	100 µg/kg	Muscle	
			150 µg/kg	Skin and fat	
			500 µg/kg	Liver	
			250 µg/kg	Kidney]

Textual Amendments

F43 Inserted by Commission Regulation (EC) No 2908/2000 of 29 December 2000 amending Annexes I and II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

[^{F43}2.4.2. Quinazolone derivatives

Pharmacological active substance(s)	Milk residue	Animal species	MRLs	Target tissues	Other provisions
Halofuginone	Halofuginone	Bovine	10 µg/kg	Muscle	Not for use in animals from which milk is produced for human consumption
			25 µg/kg	Fat	
			30 µg/kg	Liver	
			30 µg/kg	Kidney]	

[^{F8}2.4.3. Carbanilides

Pharmacological active substance(s)	Milk residue	Animal species	MRLs	Target tissues	Other provisions
Imidocarb	Imidocarb	Bovine	300 µg/kg	Muscle	
			50 µg/kg	Fat	
			2 000 µg/kg	Liver	

a [^{F14}Not for use in ovine from which milk is produced for human consumption.]]

Status: Point in time view as at 22/02/2005.

Changes to legislation: There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

			1 500 µg/kg	Kidney	
			50 µg/kg	Milk	
		[^{F14} Ovine ^a	300 µg/kg	Muscle	
			50 µg/kg	Fat	
			2 000 µg/kg	Liver	
			1 500 µg/kg	Kidney]

a [^{F14}Not for use in ovine from which milk is produced for human consumption.]

3. Agents acting on the nervous system

3.1. Agents acting on the central nervous system

3.1.1. Butyrophenone tranquillisers

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Azaperone	Sum of azaperone and azaperol	Porcine	100 µg/kg	Muscle	
			100 µg/kg	Skin and fat	
			100 µg/kg	Liver	
			100 µg/kg	Kidney	

3.2. Agents acting on the autonomic nervous system

3.2.1. Anti-adrenergics

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Carazolol	Carazolol	Porcine	5 µg/kg	Muscle	
			5 µg/kg	Skin and fat	
			25 µg/kg	Liver	
			25 µg/kg	Kidney	
[^{F6}		Bovine	5 µg/kg	Muscle	
			5 µg/kg	Fat	
			15 µg/kg	Liver	
			15 µg/kg	Kidney	
			1 µg/kg	Milk]

Status: Point in time view as at 22/02/2005.

Changes to legislation: There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

[^{F36}3.2.2. β 2 sympathomimetic agents

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Clenbuterol hydrochloride	Clenbuterol	Bovine	0,1 $\mu\text{g}/\text{kg}$	Muscle	
			0,5 $\mu\text{g}/\text{kg}$	Liver	
			0,5 $\mu\text{g}/\text{kg}$	Kidney	
			0,05 $\mu\text{g}/\text{kg}$	Milk	
		Equidae	0,1 $\mu\text{g}/\text{kg}$	Muscle	
			0,5 $\mu\text{g}/\text{kg}$	Liver	
0,5 $\mu\text{g}/\text{kg}$	Kidney]		

4. Anti-inflammatory agents

4.1. Nonsteroidal anti-inflammatory agents

4.1.1. Arylpropionic acid derivative

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
[^{F13} Carprofen	Carprofen	Bovine Not for use in animals from which milk is produced for human consumption	500 $\mu\text{g}/\text{kg}$	Muscle	
			1 000 $\mu\text{g}/\text{kg}$	Fat	
			1 000 $\mu\text{g}/\text{kg}$	Liver	
			1 000 $\mu\text{g}/\text{kg}$	Kidney	
		Equidae	500 $\mu\text{g}/\text{kg}$	Muscle	
			1 000 $\mu\text{g}/\text{kg}$	Fat	
			1 000 $\mu\text{g}/\text{kg}$	Liver	
			1 000 $\mu\text{g}/\text{kg}$	Kidney]
Vedaprofen	Vedaprofen	Equidae	50 $\mu\text{g}/\text{kg}$	Muscle	
			20 $\mu\text{g}/\text{kg}$	Fat	
			100 $\mu\text{g}/\text{kg}$	Liver	
			1 000 $\mu\text{g}/\text{kg}$	Kidney	

4.1.2. Fenamate group derivatives

Status: Point in time view as at 22/02/2005.

Changes to legislation: There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions		
[^{F9} Flunixin	Flunixin	Bovine	20 µg/kg	Muscle			
			30 µg/kg	Fat			
			300 µg/kg	Liver			
			100 µg/kg	Kidney			
			40 µg/kg	Milk			
	5-Hydroxyflunixin						
	Flunixin	Porcine	50 µg/kg	Muscle			
			10 µg/kg	Skin and fat			
			200 µg/kg	Liver			
			30 µg/kg	Kidney			
		[^{F43} Equidae	10 µg/kg	Muscle			
			20 µg/kg	Fat			
			100 µg/kg	Liver			
200 µg/kg			Kidney	II			
Tolfenamic acid	Tolfenamic acid	Bovine	50 µg/kg	Muscle			
			400 µg/kg	Liver			
			100 µg/kg	Kidney			
					50 µg/kg	Milk	
				Porcine	50 µg/kg	Muscle	
					400 µg/kg	Liver	
					100 µg/kg	Kidney	

[^{F23}4.1.3. Enolic acid derivatives

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Meloxicam	Meloxicam	Equidae	20 µg/kg	Muscle	
			65 µg/kg	Liver	
			65 µg/kg	Kidney	I

[^{F28}4.1.4. Oxican derivatives

Status: Point in time view as at 22/02/2005.

Changes to legislation: There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Meloxicam	Meloxicam	Bovine	[^{F44} 20 µg/kg]	Muscle	
			[^{F44} 65 µg/kg]	Liver	
			[^{F44} 65 µg/kg]	Kidney	
			[^{F9} 15 µg/kg]	[^{F9} Milk]	
		[^{F45} Porcine	20 µg/kg	Muscle	
			65 µg/kg	Liver	
			65 µg/kg	Kidney	II

Textual Amendments

F44 Substituted by Commission Regulation (EC) No 2728/1999 of 20 December 1999 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

F45 Inserted by Commission Regulation (EC) No 1274/2001 of 27 June 2001 amending Annex I to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

[^{F38}4.1.5. Pyrazolone derivatives

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Metamizole	4-Methylaminoantipyrin	Bovine	100 µg/kg	Muscle	
			100 µg/kg	Fat	
			100 µg/kg	Liver	
			100 µg/kg	Kidney	
			50 µg/kg	Milk	
		Porcine	100 µg/kg	Muscle	
			100 µg/kg	Skin and fat	
			100 µg/kg	Liver	
			100 µg/kg	Kidney	
		Equidae	100 µg/kg	Muscle	
			100 µg/kg	Fat	
			100 µg/kg	Liver	
100 µg/kg	Kidney		I		

Status: Point in time view as at 22/02/2005.

Changes to legislation: There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

[^{F22}4.1.6. Phenyl acetic acid derivatives

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Diclofenac	Diclofenac	Bovine ^a	5 µg/kg	Muscle	
			1 µg/kg	Fat	
			5 µg/kg	Liver	
			10 µg/kg	Kidney	
		Porcine	5 µg/kg	Muscle	
			1 µg/kg	Skin + fat	
			5 µg/kg	Liver	
			10 µg/kg	Kidney	

^a Not for use in animals from which milk is produced for human consumption.]

5. Corticoides

5.1. Glucocorticoides

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
[^{F21} Betamethasone	Betamethasone	Bovine	0,75 µg/kg	Muscle	
			2,0 µg/kg	Liver	
			0,75 µg/kg	Kidney	
			0,3 µg/kg	Milk	
		Porcine	0,75 µg/kg	Muscle	
			2,0 µg/kg	Liver	
			0,75 µg/kg	Kidney]]
Dexamethasone	Dexamethasone	Bovine	0,3 µg/kg	Milk	
		Bovine, porcine, equidae	0,75 µg/kg	Muscle	
			2 µg/kg	Liver	
			0,75 µg/kg	Kidney	
[^{F34}		Caprine	0,75 µg/kg	Muscle	
			2 µg/kg	Liver	
			0,75 µg/kg	Kidney	
			0,3 µg/kg	Milk]	

*Status: Point in time view as at 22/02/2005.***Changes to legislation:** There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

[^{F20} Methylprednisolone]	Methylprednisolone	Bovine	10 µg/kg	Muscle	Not for use in animals from which milk is produced for human consumption
			10 µg/kg	Fat	
			10 µg/kg	Liver	
			10 µg/kg	Kidney]	
[^{F46} Prednisolone]	Prednisolone	Bovine	4 µg/kg	Muscle]
			4 µg/kg	Fat	
			10 µg/kg	Liver	
			10 µg/kg	Kidney	
			6 µg/kg	Milk	

Textual Amendments

F46 Inserted by Commission Regulation (EC) No 2535/2000 of 17 November 2000 amending Annex I of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

[^{F47}6. Agents acting on the reproductive system

6.1. Progestogens

Pharmacological active substance(s)	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Chlormadinone	Chlormadinone	Bovine	4 µg/kg	Fat	For zootechnical use only
			2 µg/kg	Liver	
			2,5 µg/kg	Milk	
Flugestone acetate	Flugetone acetate	Ovine	1 µg/kg	Milk	For intravaginal use for zootechnical purposes only
		[^{F18} Caprine	1 µg/kg	Milk	For intra-vaginal use for zootechnical purposes only]
[^{F48} Altrenogest]	Altrenogest	Porcine	1 µg/kg	Skin and fat	
			0,4 µg/kg	Liver	
		Equidae	1 µg/kg	Fat	

a [^{F48}Only for zootechnical use and in accordance with the provisions of Directive 96/22/EC.]]]

Status: Point in time view as at 22/02/2005.

Changes to legislation: There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I. (See end of Document for details)

		0,9 µg/kg	Liver]
a	[^{F48} Only for zootechnical use and in accordance with the provisions of Directive 96/22/EC.]]		

Textual Amendments

F48 Inserted by Commission Regulation (EC) No 2232/2004 of 23 December 2004 amending Annexes I, II and III to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin, as regards altrenogest, beclomethasone dipropionate, cloprostenol, r-cloprostenol, sorbitan sesquioleate and toltrazuril (Text with EEA relevance).

Textual Amendments

F47 Inserted by Council Regulation (EC) No 2584/2001 of 19 December 2001 amending Annexes I and III of Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance).

Status:

Point in time view as at 22/02/2005.

Changes to legislation:

There are currently no known outstanding effects for the Council Regulation (EEC) No 2377/90 (repealed), ANNEX I.